| Autor: |
Azova M; Institute of Medicine, Peoples' Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya St, 117198 Moscow, Russia., Timizheva K; Institute of Medicine, Peoples' Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya St, 117198 Moscow, Russia.; National Medical Research Center of Cardiology of the Ministry of Healthcare of the Russian Federation, 15a 3rd Cherepkovskaya St, 121552 Moscow, Russia., Ait Aissa A; Institute of Medicine, Peoples' Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya St, 117198 Moscow, Russia., Blagonravov M; Institute of Medicine, Peoples' Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya St, 117198 Moscow, Russia., Gigani O; Institute of Medicine, Peoples' Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya St, 117198 Moscow, Russia., Aghajanyan A; Institute of Medicine, Peoples' Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya St, 117198 Moscow, Russia., Tskhovrebova L; Institute of Medicine, Peoples' Friendship University of Russia (RUDN University), 6 Miklukho-Maklaya St, 117198 Moscow, Russia.; Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, 1a Malaya Pirogovskaya St, 119435 Moscow, Russia. |
| Abstrakt: |
This study investigated the renin-angiotensin-aldosterone system (RAAS) gene polymorphisms as possible genetic risk factors for the restenosis development in patients with drug-eluting stents. 113 participants had coronary artery disease and underwent stenting. The control group consisted of 62 individuals with intact coronary arteries. Patients were divided into two groups: with in-stent restenosis (ISR) and without it. The patients with ISR were classified into subgroups by the terms of the restenosis development and age. Real-time PCR and Restriction Fragment Length Polymorphism-PCR were used to genotype the study participants for RAAS gene polymorphisms. We found that the development of restenosis is generally associated with the minor A allele for renin (REN) rs2368564 and the major TT genotype for angiotensinogen (AGT) rs699. The heterozygous genotype for AGT rs4762 acts as a protective marker. A minor A allele for angiotensin II type 2 receptor (AGTR2) rs1403543 is associated with a risk of restenosis in people under 65 years old. Among patients with the early ISR, heterozygotes for angiotensin II type 1 receptor (AGTR1) rs5186 are more frequent, as well as A allele carriers for AGTR2 rs1403543. A minor homozygous genotype for REN rs41317140 and heterozygous genotype for aldosterone synthase (CYP11B2) rs1799998 are predisposed to the late restenosis. Thus, to choose the effective treatment tactics for patients with coronary artery disease, it is necessary to genotype patients for the RAAS polymorphisms, which, along with age and clinical characteristics, will allow a comprehensive assessment of the risk of the restenosis development after stenting. |
